Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation

Cell Death and Differentiation

Volumn 21, Issue 6, 2014, Pages 854-863

  Byun, M R ^a   Hwang, J H ^a   Kim, A R ^a   Kim, K M ^a   Hwang, E S ^b   Yaffe, M B ^c   Hong, J H ^a  

^a Korea University   (South Korea)

^b Ewha Womans University   (South Korea)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Hippo pathway; osteoblast; PP1A; TAZ; Wnt

Indexed keywords

ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN; PROTEIN 14 3 3; PROTEIN HIPPO; PROTEIN PHOSPHATASE 1A; PROTEIN TAZ; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN; HIPPO PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TAZ PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STEM CELL; WNT SIGNALING PATHWAY; 3T3 CELL LINE; ANIMAL; BONE DEVELOPMENT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

14-3-3 PROTEINS; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MICE; NIH 3T3 CELLS; OSTEOBLASTS; OSTEOGENESIS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT3A PROTEIN;

EID: 84899951327     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.8     Document Type: Article

References (48)

1. Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. Embo J 2000; 19: 6778-6791.
2. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005; 309: 1074-1078.
3. Mahoney Jr WM, Hong JH, Yaffe MB, Farrance IK. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J 2005; 388(Pt 1): 217-225.
4. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009; 284: 14347-14358.
5. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009; 284: 13355-13362.
6. Park KS, Whitsett JA, Di Palma T, Hong JH, Yaffe MB, Zannini M. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. J Biol Chem 2004; 279: 17384-17390.
7. Murakami M, Nakagawa M, Olson EN, Nakagawa O. A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. Proc Natl Acad Sci USA 2005; 102: 18034-18039.
8. Murakami M, Tominaga J, Makita R, Uchijima Y, Kurihara Y, Nakagawa O et al. Transcriptional activity of Pax3 is co-activated by TAZ. Biochem Biophys Res Commun 2006; 339: 533-539.
9. Varelas X, Sakuma R, Samavarchi-Tehrani P, Peerani R, Rao BM, Dembowy J et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008; 10: 837-848.
10. Jeong H, Bae S, An SY, Byun MR, Hwang JH, Yaffe MB et al. TAZ as a novel enhancer of MyoD-mediated myogenic differentiation. Faseb J 2010; 24: 3310-3320.
11. Jang EJ, Jeong H, Han KH, Kwon HM, Hong JH, Hwang ES. TAZ Suppresses NFAT5 Activity through Tyrosine Phosphorylation. Mol Cell Biol 2012; 32: 4925-4932.
12. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13: 877-883.
13. Varelas X, Wrana JL. Coordinating developmental signaling: novel roles for the Hippo pathway. Trends Cell Biol 2012; 22: 88-96.
14. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505.
15. Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol 2012; 22: 339-346.
16. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-477.
17. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205.
18. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
19. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004; 131: 1663-1677.
20. Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Hum Genet 2004; 74: 866-875.
21. Kwee ML, Balemans W, Cleiren E, Gille JJ, Van Der Blij F, Sepers JM et al. An autosomal dominant high bone mass phenotype in association with craniosynostosis in an extended family is caused by an LRP5 missense mutation. J Bone Miner Res 2005; 20: 1254-1260.
22. Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 2007; 22: 708-716.
23. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA 2nd et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002; 157: 303-314.
24. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 2007; 22: 1924-1932.
25. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005; 102: 3324-3329.
26. Glass 2nd DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-764.
27. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005; 280: 21162-21168.
28. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010; 30: 3071-3085.
29. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S et al. Role of TAZ as Mediator of Wnt Signaling. Cell 2012; 151: 1443-1456.
30. Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol 2007; 27: 6383-6395.
31. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem 2010; 285: 37159-37169.
32. Huang W, Lv X, Liu C, Zha Z, Zhang H, Jiang Y et al. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem 2012; 287: 26245-26253.
33. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28: 2426-2436.
34. Liu CY, Lv X, Li T, Xu Y, Zhou X, Zhao S et al. PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. J Biol Chem 2011; 286: 5558-5566.
35. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA et al. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010; 18: 579-591.
36. Imajo M, Miyatake K, Iimura A, Miyamoto A, Nishida E. A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. Embo J 2012; 31: 1109-1122.
37. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011; 332: 458-461.
38. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, Schwartz RJ et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci Signal 2011; 4: ra70.
39. Konsavage Jr WM, Kyler SL, Rennoll SA, Jin G, Yochum GS. Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem 2012; 287: 11730-11739.
40. Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Mol Cell Biol 2007; 27: 6383-6395.
41. Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, Takeuchi T et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 2008; 294: F542-F553.
42. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. Embo J 2004; 23: 790-799.
43. Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 2005; 102: 17406-17411.
44. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011; 17: 684-691.
45. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003; 18: 960-974.
46. Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci USA 2007; 104: 1631-1636.
47. Yang JY, Cho SW, An JH, Jung JY, Kim SW, Kim SY et al. Osteoblast-targeted overexpression of TAZ increases bone mass in vivo. PLoS One 2013; 8: e56585.
48. Byun MR, Jeong H, Bae SJ, Kim AR, Hwang ES, Hong JH. TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol. Bone 2012; 50: 364-372.